Scientific publications

Clinical Performance of Commercial ISAC 112 Allergen Microarray Versus Noncommercial RIRAAF Platform for the Diagnosis of Plant Food and Olive Pollen Allergies

Jun 1, 2016 | Magazine: Journal of Investigational Allergology & Clinical Immunology

Martínez-Aranguren R (1), Martínez-Botas J (2), Díaz-Perales A (3), Villalba M (4), de la Hoz B (5), Gómez F (6), Bartra J (7), Blanca-López N (8), Alvarado MI (9), Moya C (10), Feo Brito F (11), Alonso MD (12), González-Mancebo E (13), Terrados S (14), García BE (13), Gamboa P (15), Parra A (16), D Amelio C (1), Goikoetxea MJ (1), Sanz ML (1).

The combination of molecular biology and technological advances in recent years has enabled the development of new methods for the determination of serum speci c IgE (sIgE) [1] to di erent allergens using a single determination method with minimal quantities of allergen and serum [2].

However, to achieve an accurate diagnostic assessment, it is still important to apply an adequate panel of allergens [3]. The ImmunoCAP ISAC 112 microarray (Thermo Fisher Scienti c) is the only commercially available allergenic protein microarray, but its current panel of allergens does not seem to have the best accuracy when it comes to diagnosing food or pollen allergies in certain regions [3].

Indeed, some authors have even suggested including other allergens [3,4]. As part of the Spanish National Research Network of adverse reactions to allergens and drugs (RIRAAF), our team recently developed a new allergenic protein microarray model.

The aim of this study was to compare the diagnostic performance of the commercial ISAC 112 microarray and the RIRAAF microarray for the study of allergies to certain fruit (peach, apple, kiwifruit), olive pollens, and nuts in a Mediterranean area.

CITATION  J Investig Allergol Clin Immunol. 2016 Jun;26(3):185-7. doi: 10.18176/jiaci.00168.